| | 
| | |  |  | Webcast
Idera Pharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference (Replay)
02/08/10 at 11:00 a.m. ET |
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered... More >> | | |
|
| Date | Title | | | 02/02/10 | Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2010| Cambridge, MA, February 2, 2010 – Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its drug discovery and development programs and provide a general corporate overview at the 12h Annual BIO CEO & Investor Conference on Monday, February 8, at 11:00 a.m. EST at the Waldorf Astoria Hotel in New York.
The pres... |
|  | | 01/28/10 | Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a
Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications| CAMBRIDGE, Mass., Jan 28, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced initiation of
a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like
Receptor (TLR) 7 and TLR9.
"As an antagonist of TLR7 and TLR9, IMO-3100 has a novel mechanism of
action and presents a potentially innovative approach in the treatment
of a number of autoimmune diseases," said Sudhir Agrawal, D.Phil., Chief
Executive Officer and Chief Sc... |
| | | 01/26/10 | Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss,
Ph.D., to Its Board of Directors| CAMBRIDGE, Mass., Jan 26, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the election
of Malcolm MacCoss, Ph.D., FRSC, to the Company's Board of Directors as
a class II director. Dr. MacCoss has nearly 30 years of drug discovery
and development experience with large international pharmaceutical
companies.
"Dr. MacCoss' extensive accomplishments include critical contributions
to bringing many important drugs to market," ... |
| | | 01/19/10 | Idera Pharmaceuticals Announces Achievement of Clinical Milestone
Under Its Collaboration with Merck KGaA for Cancer Treatment| - Merck KGaA Initiates Phase 2 Clinical Trial in Patients with Head and Neck Cancer -CAMBRIDGE, Mass., Jan 19, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has
achieved a milestone under its worldwide licensing and collaboration
agreement with Merck KGaA, Darmstadt, Germany. The milestone was
achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD
1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in co... |
| |
|
|
| There are currently no events scheduled. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
| |
